Patient No. | Sex | Age | Diagnosis | RF | ACPA | Time of Evolution, Yrs | Treatment | CC Dose |
---|---|---|---|---|---|---|---|---|
1 | F | 67 | RA | Pos | Pos | 10 | MTX | 0 |
2 | F | 58 | RA | Pos | Pos | 8 | MTX + PRED | 15 mg/day |
3 | F | 58 | RA | Pos | Pos | 13 | NSAID | 0 |
4 | M | 47 | RA | Pos | Pos | 10 | MTX | 0 |
5 | M | 47 | RA | Pos | Pos | 5 | MTX | 0 |
6 | F | 82 | RA | Pos | ND | 12 | LEF + PRED | 10 mg/day |
7 | F | 43 | RA | Neg | Neg | 4 | MTX | 0 |
8 | F | 55 | RA | Neg | Neg | 2 | NSAID | 0 |
9 | F | 42 | RA | Neg | ND | 9 | MTX + PRED | 5 mg/day |
10 | F | 42 | RA | Neg | ND | 12 | MTX + PRED | 7.5 mg/day |
11 | F | 43 | RA | Neg | Neg | 3 | Anti-TNF | 0 |
12 | F | 78 | RA | Neg | Neg | 1 | Anti-TNF | 0 |
13 | F | 45 | RA | Neg | Neg | 8 | MTX + LEF + PRED | 7.5 mg/day |
14 | F | 43 | PsA | Neg | Neg | 3 | MTX | 0 |
15 | F | 20 | PsA | Neg | Neg | 3 | MTX | 0 |
16 | M | 44 | PsA | Neg | Neg | 4 | MTX + NSAID | 0 |
17 | M | 54 | PsA | Neg | Neg | 3 | Anti-TNF | 0 |
18 | M | 48 | PsA | Neg | Neg | < 1 | None | 0 |
19 | M | 70 | PsA | Neg | Neg | 6 | MTX | 0 |
20 | F | 44 | PsA | Neg | Neg | 1 | MTX + NSAID | 0 |
21 | F | 52 | PsA | Neg | ND | 4 | None | 0 |
22 | M | 41 | PsA | Neg | ND | 10 | MTX | 0 |
23 | M | 61 | PsA | Neg | ND | 13 | MTX + NSAID | 0 |
24 | M | 42 | PsA | Neg | ND | 6 | NSAID | 0 |
25 | F | 52 | PsA | Neg | ND | 4 | NSAID | 0 |
26 | M | 27 | PsA | Neg | ND | 1 | MTX + NSAID | 0 |
27 | M | 41 | PsA | Neg | ND | 1 | NSAID | 0 |
28 | M | 31 | PsA | Neg | ND | 7 | Anti-TNF | 0 |
RA: rheumatoid arthritis; ACPA: anticitrullinated protein antibodies; CC: corticosteroids; Pos: positive; Neg: negative; ND: not determined; MTX: methotrexate; NSAID: nonsteroidal antiinflammatory drug; PRED: prednisone; LEF: leflunomide; anti-TNF: anti-tumor necrosis factor; RF: rheumatoid factor; PsA: psoriatic arthritis.